Objective
to report the 3-year clinical outcomes of coronary artery disease treatment with ultrathin-stent BP-SES (Orsiro) as compared to thick-strut BP-SES (BioMatrix)
Study
prospective, multicentre, randomised trial (non inferior)
Population
patients with chronic angina or acute coronary syndromes
Endpoints
target lesion failure: cardiac death, MI and target lesion revascularisation at 3 years
Conclusion
the ultrathin-stent biodegradable polymer sirolimus eluting stent (Orsiro) is superior to the biodegradable polymer biolimus-eluting thick-strut stent (BioMatrix) in terms of lesser target lesion failure at 3 years
Yoon et al. Circulation Cardiovasc. Interv. 2023; 16: e00089